Researcher profile · Semantic Scholar

G. Dackus

h-index: 10
Works: 29
Citations: 407

Most-cited papers

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy
V. D. de Jong, Yuwei Wang, N. T. ter Hoeve, M. Opdam +32 more
2022Journal of Clinical Oncology103 citations Open access
Semantic Scholar
Deep learning-based breast cancer grading and survival analysis on whole-slide histopathology images
Suzanne C. Wetstein, V. D. de Jong, N. Stathonikos, M. Opdam +4 more
2022Scientific Reports100 citations Open access
Semantic Scholar
Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
M. Droog, E. Nevedomskaya, Yongsoo Kim, T. Severson +14 more
2016Cancer Research35 citations Open access
Semantic Scholar
The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer
M. V. van Ramshorst, der Loo Margriet van der Heiden-van, G. Dackus, S. Linn +1 more
2016Breast Cancer Research and Treatment33 citations Open access
Semantic Scholar
Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors
M. Droog, E. Nevedomskaya, G. Dackus, R. Fles +9 more
2017Proceedings of the National Academy of Sciences of the United States of America27 citations Open access
Semantic Scholar
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial
P. Schouten, G. Dackus, S. Marchetti, H. van Tinteren +3 more
2016Trials19 citations Open access
Semantic Scholar
159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group
V. D. de Jong, Y. Wang, M. Opdam, N. T. ter Hoeve +15 more
2020Annals of Oncology17 citations Open access
Semantic Scholar
Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study
G. Dackus, N. T. ter Hoeve, M. Opdam, W. Vreuls +29 more
2017BMJ Open15 citations Open access
Semantic Scholar
Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
G. Dackus, K. Jóźwiak, G. Sonke, E. van der Wall +4 more
2021Journal of the National Cancer Institute11 citations Open access
Semantic Scholar
Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer
L. D. de Boo, K. Jóźwiak, N. T. ter Hoeve, P. V. van Diest +46 more
2024ESMO Open10 citations Open access
Semantic Scholar
Tamoxifen induces PI3K activation in uterine cancer
Kirsten Kübler, A. Nardone, Shankara K. Anand, Daniel Gurevich +30 more
2025Nature Genetics9 citations Open access
Semantic Scholar
Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer.
Yoni Schirris, R. Voorthuis, M. Opdam, M. Liefaard +17 more
2025The Lancet Digital Health8 citations Open access
Semantic Scholar
Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status
Yuwei Wang, G. Dackus, E. Rosenberg, S. Cornelissen +23 more
2024BMC Medicine6 citations Open access
Semantic Scholar
A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
J. Geenen, G. Dackus, P. Schouten, D. Pluim +7 more
2019International Journal of Cancer6 citations Open access
Semantic Scholar
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.
Yuwei Wang, A. Broeks, D. Giardiello, M. Hauptmann +15 more
2023European Journal of Cancer5 citations Open access
Semantic Scholar
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
G. Dackus, K. Jóźwiak, E. van der Wall, P. V. van Diest +4 more
2020Breast Cancer Research and Treatment3 citations Open access
Semantic Scholar
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.
Y. Wang, D. Drubay, S. Jonas, J. Dixon-Douglas +63 more
2026Annals of Oncology2 citations Open access
Semantic Scholar
Abstract GS2-09: Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations
Kirsten Kübler, A. Nardone, Shankara K. Anand, Daniel Gorvich +25 more
2022Cancer Research1 citations
Semantic Scholar
Invasive lobular breast cancer in young patients without adjuvant systemic treatment: 15-year survival outcomes
R. Voorthuis, M. Opdam, N. T. ter Hoeve, M. D. da Silva +6 more
2026Breast Cancer Research and Treatment0 citations Open access
Semantic Scholar
ECTIL: Label-efficient Computational Tumour Infiltrating Lymphocyte (TIL) assessment in breast cancer: Multicentre validation in 2,340 patients with breast cancer
Yoni Schirris, R. Voorthuis, M. Opdam, M. Liefaard +17 more
2025arXiv.org0 citations
Semantic Scholar
External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients
Y. Wang, G. Dackus, A. Broeks, D. Giardiello +15 more
2022European Journal of Cancer0 citations
Semantic Scholar
Response to Klar and Adams.
G. Dackus, K. Jóźwiak, M. Hauptmann, S. Linn
2021Journal of the National Cancer Institute0 citations Open access
Semantic Scholar
9P BRCA1 promoter methylation confers a more favorable prognosis to systemically untreated young triple-negative breast cancer patients than tumour BRCA1 mutation
Y. Wang, E. Rosenberg, G. Dackus, A. Broeks +16 more
20210 citations Open access
Semantic Scholar
Tumor size and overall survival in a cohort of young (≤40 years), nodenegative, systemically untreated breast cancer patients; by the PARADIGM study group
V. D. de Jong, N. T. ter Hoeve, M. Opdam, W. Vreuls +16 more
2019Annals of Oncology0 citations Open access
Semantic Scholar
Long-term outcome of breast cancer patients diagnosed ≤40 years according to breast cancer subtype in the absence of adjuvant systemic therapy: The PARADIGM initiative.
G. Dackus, N. T. ter Hoeve, M. Opdam, W. Vreuls +15 more
20170 citations
Semantic Scholar
Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer
M. V. van Ramshorst, der Loo Margriet van der Heiden-van, G. Dackus, S. Linn +1 more
2016Breast Cancer Research and Treatment0 citations Open access
Semantic Scholar
Optimal endocrine therapy for breast cancer patients 45-50 years of age at diagnosis.
G. Dackus, K. Jóźwiak, G. Sonke, E. van der Wall +4 more
20160 citations
Semantic Scholar
Netherlands Breast Cancer Project (NBCP): a feasibility project using data from the population based cancer registry combined with biobanking
G. Dackus, S. Siesling, N. T. ter Hoeve, N. Stathonikeos +5 more
20140 citations
Semantic Scholar
I followed by a randomized phase II trial of two cycles carboplatin-olaparib
P. Schouten, G. Dackus, S. Marchetti, H. van Tinteren +3 more
0 citations
Semantic Scholar

G. Sonke

×14

S. Siesling×14

N. T. ter Hoeve×13

M. Hauptmann×12

V. D. de Jong×10

N. Stathonikos×10

E. Koop×10

W. Vreuls×9